Ki67 and TNFRII as Potential Clinical Markers for Effective Clinical Staging of Advanced Prostate Cancer
Cancers · 13.08.2025 · 17 (16) · 2638
DOI: 10.3390/cancers17162638 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 13.08.2025. Verfasst von Edyta Idalia Wolny-Rokicka und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Histology and Developmental Biology, Faculty of Health Sciences, Pomeranian Medical University, Żołnierska 48, 71-210 Szczecin, Poland. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The statutory budget of the Pomeranian Medical University in Szczecin, Pomeranian Medical University in Szczecin.
Abstract (Originalsprache)
Background
Currently, it is a priority to develop prognostic biomarkers that would allow the identification of patients with progressing prostate diseases with a low risk of progression, so that unnecessary treatment and patient burden can be avoided.
Objectives
This study aimed to assess the clinical features and concentrations of selected mediators of apoptosis, markers of inflammation, and immunoexpression of Ki67 and selected mediators of inflammation in patients with PCa after prostatectomy procedures and who underwent palliative radiotherapy for bone metastases, as well as patients with benign prostatic hyperplasia (BPH).
Methods
A total of 88 patients, including 54 cases with PCa and 34 with BPH, were included. Stage and tumor grades were determined according to Gleason’s grading system. Immunoenzymatic methods were used to determine apoptotic and inflammatory mediators in serum, as well as deoxynucleotidyl transferase-mediated dUTP Nick End Labeling (TUNEL) reaction, and immunohistochemistry to determine selected markers of inflammation and Ki67 expression.
Results
Strong differentiating indicators were revealed, such as Ki67, and tumor necrosis factor receptor 2. Ki-67 expression was significantly associated with the Gleason score. In turn, the tumor necrosis factor receptor 2 (TNFRII) showed the highest expression in the inflammatory environment of cancer in the metastatic stage.
Conclusions
Ki67 and TNFRII can be classified as high-value clinical markers. These factors may be treated as markers regarding future information about the implementation or withdrawal of more aggressive treatment to possibly avoid toxic complications associated with both increased doses in radiotherapy and prolonged hormonal therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Histology and Developmental Biology, Faculty of Health Sciences, Pomeranian Medical University, Żołnierska 48, 71-210 Szczecin, Poland.
ORCID-Profile: Edyta Idalia Wolny-Rokicka, Marta Grabowska
Förderung
- The statutory budget of the Pomeranian Medical University in Szczecin
- Pomeranian Medical University in Szczecin
Zitieren
APA
Wolny-Rokicka, E. I., & Grabowska, M. (2025). Ki67 and TNFRII as Potential Clinical Markers for Effective Clinical Staging of Advanced Prostate Cancer. Cancers, 17(16), 2638. https://doi.org/10.3390/cancers17162638
Vancouver
Wolny-Rokicka EI, Grabowska M. Ki67 and TNFRII as Potential Clinical Markers for Effective Clinical Staging of Advanced Prostate Cancer. Cancers. 2025;17(16):2638. doi:10.3390/cancers17162638
BibTeX
@article{WolnyRokicka2025,
author = {Wolny-Rokicka, Edyta Idalia and Grabowska, Marta},
title = {Ki67 and TNFRII as Potential Clinical Markers for Effective Clinical Staging of Advanced Prostate Cancer},
journal = {Cancers},
year = {2025},
volume = {17},
number = {16},
pages = {2638},
doi = {10.3390/cancers17162638}
}
EUVIMED